In the News


September 20, 2023

A combination immunotherapy developed by biotech company Agenus administered before surgery destroyed over 80% of a tumor before it was removed.


July 10, 2023

Patients with non-microsatellite instability-high metastatic colorectal cancer had better survival rates from the botensilimab and balstilimab combination.

Targeted Oncology

July 6, 2023

The combination of botensilimab and balstilimab combination showed a survival benefit, regardless of RECIST 1.1 responses, among patients with metastatic, heavily pretreated, microsatellite stable colorectal cancer.


July 5, 2023

The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.